    Nachum Rosman | MultiView Inc | ZoomInfo.com


Insider Trading - Rosman Nachum - Form 4 SEC Filings












Home |
Archives |
Products |
About |
Contact |
FAQ |



New User?
Sign Up | 
Sign In









Form 4 Filings


Insider Buys


Significant Buys


Penny StocksInsider Buying


Insider Sales




Insider Buy Sell Ratios


Stock Options


Insider TradingStock Screener


Insider TradingGraph View


Insider Watch





Sec Filings Insider Trading - Rosman Nachum





Select Time period: 
1 Month
2 Months
3 Months
6 Months
1 Year
2 Years
3 Years
4 Years
All Data
 

     



google

   



yahoo!



Send this page to:  

Blog
  



Digg

  



Reddit

  



Facebook

  



Stumble

  



del.icio.us








Enter Stock Ticker Symbol or Cik:




Cik Lookup...






Search By Company or Insider Name:







"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch ==>>

What is insider trading>>



Email a friend >>...







Historical filings delayed by 6 months. New user?
Sign Up for real time data.
Existing user?
Sign In

Stock options: Exercise, Award, Grant, Conversion



TransactionDate
ReportedDate
ExercisableExpiration
Company
Symnbol
InsiderRelationship
SharesTraded
ConversionPrice
SharesOwned
Filing




2016-12-29Option Award
2016-12-294:10 pm
N/AN/A
Pluristem Therapeutics Inc
PSTI
Rosman NachumDirector
66,500
$0
387,464(Indirect)
View


2016-01-05Option Award
2016-01-074:10 pm
N/AN/A
Pluristem Therapeutics Inc
PSTI
Rosman NachumDirector
49,000
$0
320,964(Indirect)
View









    © 2005-2017 SecForm4.Com All rights reserved.
    Archives:
    2017 2016 2015 2014 2013 2012 ... 
    Fri, 28 Jul 2017 07:25:23 -0500
  

    SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
    SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC).
Terms of Use |
    Privacy Statement |
  









Security Check Required




FacebookJoin or Log Into Facebook   Email or PhonePasswordForgot account?Log InDo you want to join Facebook?Sign UpSign UpSecurity CheckPlease enter the text belowCan't read the text above?Try another text or an audio captchaText in the box:What's this?Security CheckThis is a standard security test that we use to prevent spammers from creating fake accounts and spamming users.SubmitEnglish (US)EspañolFrançais (France)中文(简体)العربيةPortuguês (Brasil)Italiano한국어Deutschहिन्दी日本語MessengerFacebook LitePeoplePlacesGamesLocationsCelebritiesMarketplaceGroupsRecipesMomentsInstagramAboutCreate AdCreate PageDevelopersCareersPrivacyCookiesAd ChoicesTermsSettingsActivity Log Facebook © 2017


Nachum  Rosman, Board Dir., Pluristem Therapeutics Inc.














A publisher of Business Information since 1983   
  





 


   

Search Business Search Executive 
  Advanced Search 




  

Sign In  |  Hints 









Profile of Nachum Rosman 





 


Nachum Rosman

 

Board Dir. - Pluristem Therapeutics Inc.

 


Nachum Rosman Email :
Please login 

 

Company Name : 
Pluristem Therapeutics Inc. 

 

Company Website : 
www.pluristem.com 

 

Company Address : 
Matam Advanced Technology Pk.No. 20, Haifa, ,Israel, 


 


Nachum Rosman Profile :
Board Dir. - Pluristem Therapeutics Inc. 

 


Nachum Rosman Biography :


Mr. Rosman is an expert in finance management and organization. He has held Chief Executive and CFO positions in Israel USA and England. He has operated in High-Tech global companies in Software and Business. In these jobs he was responsible for finance management fund-raising acquisitions technology sales preparation of financial reports for due diligences etc.Mr. Rosman serves as a consultant to start up companies in financing strategy and reorganization. He serves as the CEO of Multiview Ltd a company he co-founded in 1999. He serves as a director at Zoomix data mastering and Knolan.Mr. Rosman was a director actively involved in the sale of New Dimension Ltd. to B.M.C. Inc. for $675 million. Prior to that he held a Co-CEO position in R.T.S. Ltd. (Virinet Ltd.) where he participated in the IPO in NASDAQ. 

 


Nachum Rosman Colleagues :





Name 
Title 
Email 


Zami Aberman 
Co - Chmn., CEO, Pres. 
Please login 


Yaky Yanay 
VP - Finance, CFO 
Please login 


William Prather 
Sr. VP - Corporate Development 
Please login 


Shai Meretzki 
Founder, CTO 
Please login 


Ora Burger 
VP - Development 
Please login 













            Home  |  About Us  |  Product Information   |  Subscription  |  List Builder   |  Executive List   |  Email Lists   |  Contact Us  |  Site Map  |  Browse Directory    





 

© 2009, Walkers's Research - A publisher of Business Information since 1983, All Rights Reserved.














 





PSTI Nachum Rosman Insider Trades for Pluristem Therapeutics Inc.


































Bulletin






Investor Alert







New York Markets Open in:



Market Snapshot
Analyst Ratings


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Pluristem Therapeutics Inc.

                  NASDAQ: PSTI
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Pluristem Therapeutics Inc.



Market closed
 --Quotes are delayed by 20 min
Jul 27, 2017, 3:59 p.m.


PSTI

/quotes/zigman/108591/composite


$
1.17




Change

-0.05
-4.10%

Volume
Volume 393,183
Quotes are delayed by 20 min








/quotes/zigman/108591/composite
Previous close

$
			1.22
		


$
				1.17
			
Change

-0.05
-4.10%





Day low
Day high
$1.15
$1.24










52 week low
52 week high

            $1.04
        

            $1.85
        


















Insider Activity


Individual




Nachum Rosman



Mr. Nachum Rosman is Independent Director at Pluristem Therapeutics, Inc., Chief Financial Officer at Talecity Ltd., and Chief Executive Officer at Multiview Ltd. He is on the Board of Directors at Pluristem Therapeutics, Inc. and Zoomix Data Mastering Ltd.
He received his undergraduate degree from the Technion-Israel Institute of Technology and a graduate degree from the Technion-Israel Institute of Technology.



Transactions


Date
Shares
Transaction
Value





12/29/2016
66,500


 
Award at $0 per share.


0


01/05/2016
49,000


 
Award at $0 per share.


0


01/08/2015
49,000


 
Award at $0 per share.


0


02/24/2014
45,000


 
Disposition at $4 per share.


180,000


02/10/2014
35,000


 
Disposition at $4.02 per share.


140,700


12/26/2013
50,000


 
Award at $0 per share.


0


11/11/2013
22,244


 
Disposition at $3.29 per share.


73,183


11/08/2013
45,000


 
Disposition at $3.26 per share.


146,700


06/27/2013
85,000


 
Award at $0 per share.


0


08/10/2012
55,000


 
Disposition at $4.25 per share.


233,750





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Mr. Zami  Aberman 
Chairman & Co-Chief Executive Officer




Mr. Yaky  Yanay 
President, Co-Chief Executive Officer & Director




Mr. Erez  Egozi 
Chief Financial Officer & Treasurer




Dr. Esther  Lukasiewicz-Hagai 
Vice President-Clinical & Medical Affairs




Dr. Racheli  Ofir 
Vice President-Research & Intellectual Property




Dr. Hillit Mannor Shachar 
Vice President-Business Development




Dr. Moria  Kwiat 
Director




Ms. Hava Klemperer Meretzki 
Director




Mr. Isaac  Braun 
Director




Mr. Mark S. Germain 
Director




Mr. Efrat  Kaduri 
Manager-Investor & Public Relations




Ms. Karine  Kleinhaus 
Vice President-North America Division & IR Contact




Ms. Efrat  Livne-Hadass 
Vice President-Human Resources




Mr. Doron  Shorrer 
Independent Director




Mr. Israel  Ben-Yoram 
Independent Director




Mr. Nachum  Rosman 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




8:25 AM EDT
July 28, 2017


/marketstate/country/us
New York

	Pre


/marketstate/country/uk
London

	Open


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
8:25aTreasury yields edge higher ahead of GDP data
8:23aEddie Lampert's hedge fund says it may sell some or all its Sears Canada shares
8:23aGold slips, even with dollar lower, ahead of GDP report expected to show a rebound
8:23aApptio started at outperform with $25 stock price target at Oppenheimer
8:22aAlexion Pharmaceuticals upgraded to outperform from perform at Oppenheimer
8:21aMerck says it issued conservative guidance due to recovery from cyber attack in late June
8:19aNuVasive downgraded to neutral from outperform at Baird
8:19aA provocative new analysis suggests you don’t have to take all your antibiotics after all
8:18aWhat Donald Trump’s battle of wills with Jeff Sessions teaches you about a difficult boss
8:18aScaramucci says Trump’s love of cheeseburgers shows he’s not an elitist — 5 ways rich people act humble
8:17aTeekay Offshore Partners downgraded to market perform from outperform at Raymond James
8:17a5 weird things I found out about America in my first 24 hours 
8:17aElectronic Arts shares slide 3% as outlook falls short
8:16aIntel stock price target raised to $41 from $39 at Stifel Nicolaus
8:15aUPS stock price target raised to $103 from $100 at Stifel Nicolaus
8:15aMeet the ‘Hamilton’ actors who fly cross-country and play up to 18 roles in the hit show
8:15aExpedia stock price target raised to $160 from $135 at Stifel Nicolaus
8:14aAmazon stock price target raised to $1,100 from $1,075 at Stifel Nicolaus
8:13aHawaiian Holdings upgraded to hold from sell at Stifel Nicolaus
8:13aStarbucks stock price target cut to $58 from $66 at Stifel Nicolaus
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,796.55

+85.54
+0.39%





nasdaq

/quotes/zigman/12633936/realtime
6,382.19

-40.56
-0.63%





s&p 500

/quotes/zigman/3870025/realtime
2,475.42

-2.41
-0.10%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15






















































 

Nachum Rosman's involvement in venture capital (via Pluristem Therapeutics Inc)































Want to see more?Want to find out who got funded, and who’s funding the next big thing? in real time? all across the world? tailored to your specific areas of focus?100+ deals per dayGet access to the most exhaustive worldwide funding watch on the web!Comprehensive funding informationKnow about who invested in a company, which sites covered the event, the funding history, etc.Exclusive insightsView original analytics such as most dynamic industries, most active investors, and more!Stay aware!Get emailed when deals critical to your business happen. Filter by region, industry and topics of interest.As seen onHave a login?Sign inRegister now!It's free!Use your social accountOr fill in the quick form:Register nowpromise we won't spamSign invia your social account:via your existing WGF account:Remember meRegister, it's freeForgot your password?SIGN INForgot your password?Enter your e-mail and we will send you your new password.reset passwordThe world's largest funding base/people/57914-nachum-rosmansection=people&subsection=detail&id=57914




			Search deals by company name, industry, location, investors...			
			




SEARCH


NachumRosmanGet alertedif Nachum Rosman gets funded!Nachum RosmanPluristem Therapeutics Inc - DirectorDeals involving Nachum Rosman$17,000,000 raised with Pluristem Therapeutics Inc on June, 2015$1,220,003 raised with Pluristem Therapeutics Inc on October, 2010$250,000 raised with Pluristem Therapeutics Inc on May, 2010Please note that all data is automatically extracted and errors can occur.The WhoGotFunded team has not necessarily reviewed the information in this page and has not determined if it is accurate and complete.Some of the profile information was collected using the Crunchbase API. For more details on the profile, please check Nachum Rosman on Crunchbase.Inaccurate Data? Help us improve WhoGotFunded: post a comment!








Nachum Rosman - Executive Bio, Compensation History, and Contacts - Equilar Atlas










 

















Log in | Sign up








x

 






As Featured In




















Nachum Rosman
Board Member at Pluristem Therapeutics Inc.


View Full Profile
Are you Nachum Rosman? Claim your profile


 


Sign up for Equilar Atlas and view Nachum Rosman's full profile. 
With Equilar Atlas, you can:



IDENTIFY corporate executives in Nachum Rosman's  network and community.
												FOLLOW changes in Nachum Rosman's employment and money-in-motion.
												CONNECT with Nachum Rosman through your network of contacts.
												








Nachum Rosman's Executive Work History


Current


Board Member, 
Pluristem Therapeutics Inc.


Past
To view Nachum Rosman's complete executive work history, sign up now
Age
71

 
 


Nachum Rosman's Biography



Mr. Rosman became a director of the Company in October 2007. He provides management and consulting services to startup companies in the financial, organizational and human resource aspects of their operations.  Mr. Rosman also serves as the CEO of Simba Ltd. and as a director at several privately held companies.  Throughout his career, Mr. Rosman held CEO and CFO positions in Israel, the United States and England.  In these positions he was responsible, among other things, for finance management, fund raising, acquisitions and technology sales.

 

Mr. Rosman holds a B.Sc. in Management Engineering and an M.Sc. in Operations Research from the ...
(Read More)

			Mr. Rosman became a director of the Company in October 2007. He provides management and consulting services to startup companies in the financial, organizational and human resource aspects of their operations.  Mr. Rosman also serves as the CEO of Simba Ltd. and as a director at several privately held companies.  Throughout his career, Mr. Rosman held CEO and CFO positions in Israel, the United States and England.  In these positions he was responsible, among other things, for finance management, fund raising, acquisitions and technology sales.

 

Mr. Rosman holds a B.Sc. in Management Engineering and an M.Sc. in Operations Research from the Technion, Haifa, Israel.  Mr. Rosman also participated in a Ph.D. program in Investments and Financing at the Tel Aviv University, Israel.

 

We believe that Mr. Rosman's qualifications to sit on our Board of Directors include his years of experience in the high-tech industry, as well as his knowledge and familiarity with corporate finance.
		
Source: Pluristem Therapeutics Inc. on 09/09/2015
		
	

 






Sign up for Equilar Atlas and view Nachum Rosman's full profile. 



												By accessing Equilar Atlas, you can view bios, network, salary and wealth events
												of industry-leading executives like Nachum Rosman. More specifically, you'll be able to:
												

IDENTIFY corporate executives in Nachum Rosman's  network and community.
												FOLLOW changes in Nachum Rosman's employment and money-in-motion.
												CONNECT with Nachum Rosman through your network of conections.
												




View Full Profile


 








Search for over 360,000 executive profiles.





/bio



													Example: Nachum Rosman


















Nachum Rosman's Connections (29)





Sign up now to view Nachum Rosman's 29 connections »









Moria Kwiat
Board Member, Pluristem Therapeutics Inc.









Hava Meretzki
Board Member, Pluristem Therapeutics Inc.









Isaac Braun
Board Member, Pluristem Therapeutics Inc.









Boaz Gur-Lavie
Former Chief Financial Officer and Secretary, Pluristem Therapeutics Inc.









Yaky Yanay
Dir., Co-Chief Executive Officer and President, Pluristem Therapeutics Inc.









Doron Shorrer
Board Member, Pluristem Therapeutics Inc.









Zami Aberman
Co-Chief Executive Officer and Chairman, Pluristem Therapeutics Inc.









Mark S. Germain
Board Member, Pluristem Therapeutics Inc.









Israel Ben-Yoram
Board Member, Pluristem Therapeutics Inc.









Shai Pines
Former Board Member, Pluristem Therapeutics Inc.








Popular Profiles






														Sign up now to view more executive profiles »
														









Thomas J. Lynch
Executive Chairman, TE Connectivity Ltd.









John J. Kita
EVP and CFO, A. O. Smith









Carl G. Annessa
EVP and COO, Hornbeck Offshore Services, Inc.









Elon R. Musk
CEO and Chairman, Tesla









Michael C. Montgomery
Board Member, NMI Holdings, Inc.












×

Claim Your Profile Coming Soon
Interested in updating your biography and work history?
We're working on making it happen.
We'll email you when this feature is available.
Please enter valid email address.

Done


Thank you for your interest.
Ok






			Browse executive profiles:
			
				 A
			
				 B
			
				 C
			
				 D
			
				 E
			
				 F
			
				 G
			
				 H
			
				 I
			
				 J
			
				 K
			
				 L
			
				 M
			
				 N
			
				 O
			
				 P
			
				 Q
			
				 R
			
				 S
			
				 T
			
				 U
			
				 V
			
				 W
			
				 X
			
				 Y
			
				 Z



Equilar Homepage
Equilar Atlas
Equilar Insight
Equilar BoardEdge
Equilar Engage
Research Services
Knowledge Network
About Us
Login

ï¿½ 2017 Equilar All Rights Reserved. Privacy Policy
1100 Marshall Street, Redwood City, CA 94063 | Phone (650) 241-6600 | Fax (650) 701-0993
















ROSMAN NACHUM Top Holdings  

































WhaleWisdom









Search All
Search 13F Filers Only
Search SEC Filer
Search Stocks Only
Search Mgmt Inv. Cos Only
ETFs Only
Search Active




















                      ROSMAN NACHUM
                    

•   TEL AVIV, L3
                      
How do I update this listing?




                                             Rosman Nachum is based out of Tel Aviv.    WhaleWisdom has at least 2 insider transactions (Form 3,4,5) in our database for Rosman Nachum. 
                                           














Summary
13D/G
Insider (Form 4)



   Create Email Alert
 




×
Email Notification.







                   ***Log In or
                   Sign-up
                   to see more advanced email alert options such as selecting any type of
                   SEC form, multiple filers or classes of filers, and much more.***
                 

                    ...or to simply have an email sent to you whenever we receive a new
                           13F filing from ROSMAN NACHUM, enter your
                    email address below and choose 'Submit'.
                

Your email:








Cancel














Contact Info




rosman nachum


FEINSTEIN 7

TEL AVIV
L3
                                                        
                                                    69123


                                                      Business Phone:
                                                      972-74-710-7171
SEC SIC CODE:2836-BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)







Recent SEC Filings




4 filed on 12/29/2016
4 filed on 01/07/2016
4 filed on 01/08/2015
4 filed on 02/26/2014
4 filed on 02/12/2014
4 filed on 12/26/2013
4 filed on 11/12/2013
4 filed on 06/27/2013
4 filed on 08/14/2012
4 filed on 12/22/2011
















Schedule 13D and 13G events since 03/31/2017

Subscription required



 
Form 4 - Non-derivative Insider Transactions Since 03/31/2017
Loading...








Elevate your investments
Try it for free


















Pluristem Therapeutics Inc (PSTI.O)  People | Reuters.com


























































X



Edition:

United States


















Africa
América Latina


عربي
Argentina


Brasil
Canada


中国
Deutschland


España
France


India
Italia


日本
México


РОССИЯ
United Kingdom

United States
















Pluristem Therapeutics Inc (PSTI.O)










Related Topics: 
StocksStock ScreenerMarket DataHealthcareBiotechnology & Medical Research












                
                        Overview
                    



                
                        News
                    



                
                        Key Developments
                    



                
                        People
                    



                
                        Charts
                    



                
                        Financials
                    



                
                        Analysts
                    



                    
                            Research
                        



                    
                            Pulse
                        










				PSTI.O on Consolidated Issue listed on NASDAQ Capital Market


				1.17USD
27 Jul 2017





				    Change	(% chg)


		    
						    --


					            (--)
					        






Prev Close

$1.17


Open

--




Day's High

--


Day's Low

--




Volume

--


Avg. Vol

233,013




52-wk High

$1.85


52-wk Low

$1.04











					Summary





Name
Age
Since
Current Position




							Yaky Yanay

45
2017

                                Chairman of the Board, Chief Executive Officer




							Zalman Aberman

61
2017

                                President, Co-Chief Executive Officer, Director




							Erez Egozi

49
2017

                                Chief Financial Officer




							Doron Shorrer

62
2006

                                Lead Independent Director




							Moria Kwiat

36
2012

                                Director




							Hava Meretzki

46
2005

                                Director




							Israel Ben-Yoram

55
2005

                                Independent Director




							Issac Braun

63
2014

                                Independent Director




							Mark Germain

65
2014

                                Independent Director




							Nachum Rosman

69
2007

                                Independent Director




							Karine Kleinhaus


2013

                                Divisional Vice President, North-America



» Insider Trading





					Biographies





Name
Description




							Yaky Yanay


					
							Mr. Yaky Yanay is Chairman of the Board, Chief Executive Officer of Pluristem Therapeutics Inc. His work experience includes the following roles: President, Chief Operating Officer at the Company (from February 4, 2014), Chief Financial Officer and Secretary at the Company (from November 1, 2006),Chief Financial Officer of Elbit Vision Systems Ltd. and Co-Chairman of Israel Advanced Technology Industries an umbrella organization representing Israel’s hi-tech and life-science industries. He holds a Bachelor of Business Administration degree from Hamichlala Leminhal. He is a Certified Public Accountant.




							Zalman Aberman


					
							Mr. Zalman (Zami) Aberman is President, Co-Chief Executive Officer, Director of Pluristem Therapeutics, Inc. He changed the Company’s strategy towards cellular therapeutics. Mr. Aberman’s vision to use the maternal section of the Placenta (Decidua) as a source for cell therapy, combined with the Company’s 3D culturing technology, led to the development of our products. Since November 2005, Mr. Aberman has served as a director of the Company, and since April 2006, as Chairman of the Board. He has 25 years of experience in marketing and management in the high technology industry. Mr. Aberman has held positions of CEO and Chairman positions in companies in Israel, the United States, Europe, Japan and Korea. Mr. Aberman operated within high-tech global companies in the fields of automatic optical inspection, network security, video over IP, software, chip design and robotics. He serves as the Chairman of Rose Hitech Ltd., a private investment company. He served in the past as the Chairman of VLScom Ltd., a private company specializing in video compression for HDTV and video over IP and as a director of Ori Software Ltd., a company involved in data management. Prior to that, Mr. Aberman served as the President and CEO of Elbit Vision System Ltd. (EVSNF.OB), a company engaged in automatic optical inspection. Prior to his service with the Company, Mr. Aberman served as President and CEO of Netect Ltd., specializing in the field of internet security software and was the Co-Founder, President and CEO of Associative Computing Ltd., which developed an associative parallel processor for real-time video processing. He also served as Chairman of Display Inspection Systems Inc., specializing in laser based inspection machines and as President and CEO of Robomatix Technologies Ltd.




							Erez Egozi


					
							Mr. Erez Egozi has been appointed Chief Financial Officer at Pluristem Therapeutics Inc. effective March 29, 2017. His work experience includes the following roles: Vice President - Finance and Secretary at the Company, Senior Director of Finance-worldwide Finance Controller at Verint's Communications and Cyber Intelligence Solutions division, has held several financial positions at Intel Corporation (2003-2007) and Auditor in the hi-tech technology sector at Deloitte & Touche (2000-2003).




							Doron Shorrer


					
							Mr. Doron Shorrer, CPA, is Lead Independent Director of Pluristem Therapeutics, Inc. Mr. Shorrer was one of the Company’s founders and served as its first Chairman until 2006. Mr. Shorrer also serves as a director of other companies: Provident Fund for employees of the Israel Electric Company Ltd. and for Hebrew University employees, and Massad Bank from the International Bank group. Between 1999 and 2004 he was Chairman of the Boards of Phoenix Insurance Company, one of the largest insurance companies in Israel, and of Mivtachim Pension Funds Group, the largest pension fund in Israel. Prior to serving in these positions, Mr. Shorrer held senior positions that included Arbitrator at the Claims Resolution Tribunal for Dormant Accounts in Switzerland; Economic and Financial Advisor, Commissioner of Insurance and Capital Markets for the State of Israel; Member of the board of directors of “Nechasim” of the State of Israel; Member Committee for the Examination of Structural Changes in the Capital Market (The Brodet Committee); General Director of the Ministry of Transport; Founder and managing partner of an accounting firm with offices in Jerusalem, Tel-Aviv and Haifa; Member of the Lecture Staff of the Hebrew University Business Administration School; Chairman of Amal School Chain; Chairman of a Public Committee for Telecommunications; and Economic Consultant to the Ministry of Energy. Among many areas of expertise, Mr. Shorrer holds a B.A. in Economics and Accounting and an M.A. in Business Administration (specialization in finance and banking) from the Hebrew University of Jerusalem and is a Certified Public Accountant in Israel.




							Moria Kwiat


					
							Dr. Moria Kwiat serves as Director of Pluristem Therapeutics, Inc. Dr. Kwiat holds a B.Sc and an M.Sc. in Biotechnology from Tel Aviv University, and a Ph.D. from the Tel Aviv University Center for Nanoscience and Nanotechnology. Dr. Kwiat served as a teaching assistant at Tel Aviv University from 2003 through 2012. Currently, Dr. Kwiat is a postdoc fellow at the Faculty of Chemistry of Tel Aviv University, working on the development of new generation of biosensors based on nano-materials.




							Hava Meretzki


					
							Ms. Hava Meretzki is Director of Pluristem Therapeutics, Inc. Ms. Meretzki is an attorney and is a partner in Meretzki law firm in Haifa, Israel. Ms. Meretzki specializes in civil, trade and labor law, and is presently the Chairman of the National Council of the Israel Bar Association. Ms. Meretzki received a Bachelors Degree in Law from the Hebrew University in 1991 and was admitted to the Israel Bar Association in 1993. We believe that Ms. Meretzki’s qualifications to sit on our Board include her years of experience with legal and corporate governance matters.




							Israel Ben-Yoram


					
							Mr. Israel Ben-Yoram is Independent Director of Pluristem Therapeutics, Inc. He has been a director and partner in the accounting firm of Mor, Ben-Yoram and Partners in Israel since 1985. In addition, since 1992, Mr. Ben-Yoram has been a shareholder and has served as the head director of Mor, Ben-Yoram Ltd., a private company in Israel in parallel to the operation of Mor, Ben-Yoram and Partners. This company provides management services, economic consulting services and other professional services to businesses. Furthermore, Mr. Ben-Yoram is the CEO of Eshed Dash Ltd. and Zonbit Ltd. During 2003-2004 Mr. Ben-Yoram served as a director of Brainstorm Cell Therapeutics Inc. (BCLI) and Smart Energy solutions, Inc. (SMGY), both of which were traded on the NASDAQ.




							Issac Braun


					
							Mr. Issac Braun is Independent Director of Pluristem Therapeutics, Inc. Mr. Braun is a business veteran with entrepreneurial, industrial and manufacturing experience. He is a co-founder and has been a board member of several hi-tech start-ups in the areas of e-commerce, security, messaging, search engines and biotechnology. Mr. Braun is involved with advising private companies on raising capital and business development.




							Mark Germain


					
							Mr. Mark S. Germain is Independent Director of Pluristem Therapeutics, Inc. Between May 2007 and February 2009, Mr. Germain served as Co-Chairman of our Board. For more than five years, Mr. Germain has been a merchant banker serving primarily the biotech and life sciences industries. He has been involved as a founder, director, chairman of the board of, and/or investor in, over twenty companies in the biotech field, and assisted many of them in arranging corporate partnerships, acquiring technology, entering into mergers and acquisitions, and executing financings and going public transactions. He graduated from New York University School of Law in 1975, Order of the Coif, and was a partner in a New York law firm practicing corporate and securities law before leaving in 1986. Since then, and until he entered the biotech field in 1991, he served in senior executive capacities, including as president of a public company, which was sold in 1991. In addition to being a Director of the Company, Mr. Germain is a director of ChromaDex, Inc. (CDXB.OB), a publicly traded company. Mr. Germain also serves as a director of the following companies that were reporting companies in the past: Stem Cell Innovations, Inc., Omnimmune Corp. and Collexis Holdings, Inc. He is also a co-founder and director of a number of private companies in and outside the biotechnology field.




							Nachum Rosman


					
							Mr. Nachum Rosman is Independent Director of Pluristem Therapeutics, Inc. He provides management and consulting services to startup companies in the financial, organizational and human resource aspects of their operations. Mr. Rosman also serves as a director at several privately held companies. Throughout his career, Mr. Rosman held CEO and CFO positions in Israel, the United States and England. In these positions he was responsible, among other things, for finance management, fund raising, acquisitions and technology sales. Mr. Rosman holds a B.Sc. in Management Engineering and an M.Sc. in Operations Research from the Technion, Haifa, Israel. Mr. Rosman also participated in a Ph.D. program in Investments and Financing at the Tel Aviv University, Israel.




							Karine Kleinhaus


					
							Ms. Karine Kleinhaus, M.D., is Divisional Vice President, North America of Pluristem Therapeutics, Inc. She has worked with multiple public and private biotechnology companies on both public and investor relations. Prior to that, she was an Assistant Professor in the Departments of Obstetrics and Gynecology and Psychiatry at the NYU School of Medicine. At NYU, Dr. Kleinhaus conducted medical research funded under a multi-year NIH grant. She published more than 25 papers in leading peer-reviewed journals such as the Annals of the New York Academy of Science, American Journal of Medical Genetics, and the American Journal of Epidemiology. Before that Dr. Kleinhaus practiced obstetrics and then completed two fellowships at Columbia University. Dr. Kleinhaus received her medical degree from Tel Aviv University, earned a Master of Public Health from Columbia’s Mailman School of Public Health, and a bachelor’s degree, cum laude, from Princeton University.











					Basic Compensation





Name
Fiscal Year Total




							Yaky Yanay

786,721




							Zalman Aberman

1,015,210




							Erez Egozi

--




							Doron Shorrer

--




							Moria Kwiat

--




							Hava Meretzki

--




							Israel Ben-Yoram

--




							Issac Braun

--




							Mark Germain

--




							Nachum Rosman

--




							Karine Kleinhaus

--



As Of 
29 Jun 2015





					Options Compensation





Name
Options
Value




							Yaky Yanay

0
0




							Zalman Aberman

0
0




							Erez Egozi

0
0




							Doron Shorrer

12,851,170
0




							Moria Kwiat

0
0




							Hava Meretzki

0
0




							Israel Ben-Yoram

8,355,089
0




							Issac Braun

8,284,594
0




							Mark Germain

0
0




							Nachum Rosman

0
0




							Karine Kleinhaus

0
0









					Insider Trading












Name
Shares Traded
Price


Egozi (Erez)
150,000
$0.00


Aberman (Zalman)
2,000,000
$0.00


Yanay (Yaky)
2,000,000
$0.00


Yanay (Yaky)
200,000
$0.00


Aberman (Zalman)
200,000
$0.00


Ben-Yoram (Israel)
66,500
$0.00


Rosman (Nachum)
66,500
$0.00


Shorrer (Doron)
66,500
$0.00


Meretzki Klemperer (Hava)
45,000
$0.00


Kwiat (Moria)
45,000
$0.00


Germain (Mark S)
65,500
$0.00


Braun (Isaac)
45,000
$0.00


Shorrer (Doron)
12,346
$1.52


Aberman (Zalman)
5,000
$1.33


Yanay (Yaky)
5,000
$1.20


Yanay (Yaky)
7,500
$0.83


Yanay (Yaky)
7,500
$1.07


Aberman (Zalman)
9,000
$1.07


Aberman (Zalman)
6,000
$1.06


Yanay (Yaky)
5,000
$0.83


Aberman (Zalman)
31,000
$0.80


Ben-Yoram (Israel)
10,000
$0.79


Meretzki Klemperer (Hava)
35,000
$0.00


Germain (Mark S)
48,000
$0.00


Yanay (Yaky)
150,000
$0.00




» Full list on Insider Trading
















Related Topics: 
StocksStock ScreenerMarket DataHealthcareBiotechnology & Medical Research




















